Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.